louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02909296: Endoscopic Drainage of Collections After Pancreatic Surgery
Official title: Endoscopic Drainage of Collections After Pancreatic Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pancreatic Cancer
Lead sponsor: Institut Paoli-Calmettes
Sponsor class: OTHER
First posted: 2016-09-21
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient having a pancreatic surgery complicated with a post-operative collection drained endoscopically

Brief summary: The pancreatic surgery causing some pancreatic collections. And in a number of case, this surgery can require a surgical resumption, a percutaneous drainage or an endoscopic drainage.

The endoscopic care of the treatment of pancreatic collections post-surgery is not yet standardized.

After failure of the medical treatment, the drainage of collections by echo-endoscopy was described.

There are not much series on this specific subject. Only 2 series contain more than 20 patients with 31 patients for the most important.

The timing and the technical choice of the endoscopic treatment as well as the long-term follow-up are not clear.

The purpose of this study is to estimate the success and the complications of the endoscopic drainage by echo-endoscopy according to the techniques of drainage and the timing of the endoscopic treatment.

The not estimated long-term follow-up will be also considered.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* Patient having a pancreatic surgery complicated with a post-operative collection drained endoscopically

Exclusion Criteria:

* Contraindication surgery

Primary outcomes:
measure: Long-term evaluation of the risk of relapse
timeFrame: Up to 6 month
measure: Timing of endoscopic drainage
timeFrame: Up to 3 month
Secondary outcomes:
measure: Immediate efficiency
timeFrame: Immediate post operative intervention
Other outcomes:
measure: Post surgery complications
timeFrame: Up to 1 month
Locations:
Study officials:
affiliation: Institut Paoli-Calmettes
name: CAILLOL Fabrice, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02649296: Effect of Skanlab Regarding Knee Arthrosis
Official title: Effect of Skanlab Regarding Knee Arthrosis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Arthrosis
Lead sponsor: Oslo Metropolitan University
Sponsor class: OTHER
First posted: 2016-01-07
Enrollment: 16
Sex: ALL
Minimum age (years): 45
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose is to find out the effect of Skanlab at knee arthrosis.

Detailed description: The patients diagnosed with knee arthrosis will be treated With Skanlab twice a week for four weeks.

Eligibility criteria: Inclusion Criteria:

* knee arthrosis in one or both legs

Exclusion Criteria:

* Pacemaker
* infusion pump
* cancer
* diabetes
* pregnancy
* blood clots
* bacteriological inflammation
* reduced sensitivity in the treatment area.

Primary outcomes:
measure: Knee injury and Osteoarthritis Outcome Score (KOOS)
timeFrame: 15 months
Secondary outcomes:
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Oslo and Akershus University college of applied science
Study officials:
affiliation: Oslo and Akershus university college of applied science
name: Trine Haugen, Prof
role: STUDY_DIRECTOR
References:
Clinical trial NCT05468996: Median Effective Dose of Remimazolam for Sedation in Elderly Patients
Official title: Median Effective Dose of Remimazolam for Sedation in Elderly Patients Undergoing Lower Limb Surgery Under Spinal Anesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Sedative
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2022-07-21
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Currently used drugs for monitored general anesthesia include propofol, midazolam, and dexmedetomidine. Each drug has different advantages and disadvantages. Remimazolam causes a relatively small decrease in blood pressure, and it has no injection pain. In addition, remimazolam has a very short onset time, and even after the continuous infusion, the onset of remimazolam is fast, and even after continuous injection, the effect disappeared very quickly due to the short context-sensitive half time. And through continuous infusion, the patient's depth of anesthesia can be maintained constant. In addition, the short duration of action and the ability to quickly reverse the effect of flumazenil suggest that remimazolam can be used effectively under general anesthesia as well as under general anesthesia. Remimazolam can be used as a continuous infusion for general anesthesia. However, it has also been reported to be used for sedation by continuous infusion or divided intravenous infusion. However, the effective maintenance dose of remimazolam for sedation without mechanical ventilation has not been established. In addition, age might be an important factor for determining the appropriate dose of remimazolam.

In this study, we aim to identify the median effective dose of remimazolam for maintaining sedation in elderly patients undergoing lower limb surgery under spinal anesthesia.


Eligibility criteria: Inclusion Criteria:

* age: equal or older than 20 years
* ASA PS: 1-3
* patients who are scheduled to undergo lower limb surgery under spinal anesthesia with sedation using remimazolam

Exclusion Criteria:

* Patients who refuse to participate in this study
* Patients with hypersensitivity to benzodiazepine or flumazenil
* Patients with severe renal/hepatic disease
* Patients with drug/alcohol abuse
* Patients who take antidepressants, anticonvulsants, psychoactive drugs chronically
* Patients with difficulty in communication
* Patients with severe obstructive sleep apnea or other airway problems
* Patients contraindicated to regional anesthesia
* Patients judged to be inappropriate for this study

Primary outcomes:
measure: success or failure of sedation maintenance
timeFrame: throughout the surgery
Secondary outcomes:
measure: respiratory depression
timeFrame: throughout the surgery
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
affiliation: Asan Medical Center
name: Won Uk Koh
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02874196: Prosthesis Loosening Imaging With Dual Energy and Tomosynthesis
Official title: Study of Diagnostic Performances of Dual Energy Imaging With Flat Detectors and Tomosynthesis in Identification of Loosening of Painful Hip Prosthesis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hip Prosthesis Imaging
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2016-08-22
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose is to determine diagnostic performances of flat panel dual energy arthrography and arthro-tomosynthesis in identification of loosening of painful hip prosthesis, taking as reference the results of surgery performed 6 months after arthrography.

Secondary purposes are:

* To describe the level of concordance of each technique with the indication for surgery
* To study inter-technique concordance with kappa coefficient
* To study the relationship between density differential between 2 acquisitions and grey level on subtraction, i.e. subtraction quality according to metal

Detailed description: Hip arthroplasty has become one of the most performed orthopedic procedures. Actual average lifetime of total hip prosthesis is approximately 15 years. Some complications are inevitable. Total hip prosthesis imaging, performed to search for a complication or wear, is difficult and depends on many techniques. Subtracted arthrography is a good technique but its access is limited because it needs an angiography room.

In this study patients undergo standard arthrography, dual energy arthrography, arthro-tomosynthesis and arthro-tomography.

Eligibility criteria: Inclusion Criteria:

* Patients sent for arthro-tomography of painful prosthesis, without contraindications to arthrography or injection of contrast agent
* Aware and cooperative
* Signed informed consent
* Affiliation to social security

Exclusion Criteria:

* Any contraindication to arthrography or injection of contrast agent
* Pregnant or possibly pregnant women
* Patient under guardianship
* Refusal or impossibility of informed consent

Primary outcomes:
measure: Presence or absence of prosthesis loosening detected with 3 radiographic techniques (dual-energy arthrography, arthro-tomosynthesis and single-energy tomography) and surgery
timeFrame: from day 0 up to 6 months
Secondary outcomes:
measure: Comparison between density differential between 2 acquisitions and grey level on subtraction
timeFrame: day 0
Other outcomes:
Locations:
city: Nancy
country: France
facility: CHU de Nancy
city: Nancy
country: France
facility: SINCAL
Study officials:
affiliation: Service d'Imagerie Guilloz - CHU Nancy - France
name: Alain Blum
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00946296: Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease
Official title: Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Graves Disease
Hyperthyroidism
Keywords: Graves Disease
Lead sponsor: University of Massachusetts, Worcester
Sponsor class: OTHER
First posted: 2009-07-24
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether a brief course of SSKI (saturated solution of potassium iodide) administered preoperatively provides any benefit in the surgical management of patients undergoing thyroidectomy as definitive management of their Graves Disease.

Detailed description: Historically Potassium Iodide was given to patients for 1 week prior to thyroidectomy. This common practice was used to decrease thyroid function and prevent thyroid storm during the thyroidectomy. However, in modern practice, nearly all patients presenting for surgical management have been made euthyroid through the use of medications such as propylthiouracil. Despite this potassium iodine continues to be administered with the presumption that it decreases the friability of the gland making surgery easier, with less blood loss.

The outcomes to be measured in this surgery are operative time, operative complications and blood loss.

Eligibility criteria: Inclusion Criteria:

* Adult patients with a clinical diagnosis of Graves Disease
* Patients who have selected surgical resection as treatment of their Graves Disease
* Prior use of anti thyroid medication so that patient is clinically and biochemically euthyroid

Exclusion Criteria:

* Patients deemed unfit for surgery by operating surgeon or anesthesist
* Patients who are clinically hyperthyroid or have T3 or T4 levels 2X the upper limit of normal

Primary outcomes:
measure: Blood Loss During Surgery
timeFrame: up to 162 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Worcester
country: United States
facility: UMASS Memorial Health Care
state: Massachusetts
Study officials:
References:
Clinical trial NCT02192996: Probiotic Supplementation to Improve the GUT Microbiota of Very Low Birth Weight Preterm, a Pilot Study
Official title: Probiotic Supplementation to Improve the GUT Microbiota of Very Low Birth Weight, a Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Other Preterm Infants
NEC
Keywords: VLBW preterm
GUT microbiota
probiotics supplementation
immune compounds
Lead sponsor: Hospital Universitario La Paz
Sponsor class: OTHER
Collaborators: name: Universidad Complutense de Madrid
First posted: 2014-07-17
Enrollment: 5
Sex: ALL
Minimum age (years): 1
Maximum age (years): 1
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: This pilot trial is designed to investigate the benefits of the use of probiotics in GUT microbiota development and/or immunological biomarkers and how this can be related with the clinical status of very low birth weight preterms during their first weeks of life at the neonatal intensive care unit(NICU).

Detailed description: This pilot trial is designed to investigate the benefits of the use of mixtures of probiotics isolated from human milk in GUT microbiota development and/or immunological biomarkers. Furthermore, the relationship between evaluated parameters and the clinical status of very low birth weight preterms during their first weeks of life at the NICU will be analysed.

Eligibility criteria: Inclusion Criteria:

* preterm infants with birth weight less than one thousand and three hundred grammes
* preterm infants with gestational age less than 29 weeks

Exclusion Criteria:

* mayor malformations
* chromosomopathies
* congenital infections
* non parental consent

Primary outcomes:
measure: changes in microbiological counts in feces of preterm infants
timeFrame: prior to initiate and at 7th, 14th, 21th, 28th days receiving probiotics
Secondary outcomes:
measure: concentration of immunological parameters on feces
timeFrame: prior to star and at 7th, 14th and 21st days of receiving probiotics
measure: concentration of immunological parameters on plasma samples
timeFrame: 7th, 14th, 19th and 24th days of receiving probiotic).
Other outcomes:
measure: clinical features during NICU stay
timeFrame: during NICU stay, arround 1 moth
Locations:
city: Madrid
country: Spain
facility: Hospital Universitario La Paz
Study officials:
affiliation: Hospital Universitario La Paz
name: Miguel Saenz de Pipaon, PhD. MD.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06962696: A Comparative Study of Large Language Model and Professional Assessment Results of the Elderly's Home Environment
Official title: A Comparative Study of Large Language Model and Professional Assessment Results of the Elderly's Home Environment
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Elderly (People Aged 65 or More)
Home Environment Related Disease
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2025-05-08
Enrollment: 20
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The elderly are older than or equal to 65 years old, regardless of gender, and have been living in Beijing for a long time.

Brief summary: This study is an investigative study, taking the elderly in Beijing community as an example, and taking photos of different areas in the home environment of the elderly who agree to participate in the study (a total of seven aspects, including pathways/entrance to home, hallways, stairs/steps, living room, kitchen, restroom, bedroom). Subsequently, the multi-modal large model GPT-4o and a professional occupational therapist will use the "Home Environment Assessment" scale to evaluate the home environment shown in the photos and give corresponding suggestions for modification. A professional occupational therapist (non-evaluator) will analyze and compare the evaluation results and guidance recommendations of GPT-4o and the evaluator, and compare whether there are any significant differences between the two analysis results.


Eligibility criteria: Inclusion Criteria:

1. Age ≥65 years old
2. Staying in the place of residence for a long time
3. Having normal listening, speaking, and comprehension skills

Exclusion Criteria:

Does not live regularly in the place of residence

Primary outcomes:
measure: Home Environment Assessment Scale
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Peking
country: China
facility: Peking University Third Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT01377896: The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours
Official title: The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Schizophrenia
Bipolar Disorders
Major Depressive Disorders
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2011-06-22
Enrollment: 221
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with cardiovascular events

Brief summary: 'Real life' retrospective patient cases (10) to provide an objective and robust analytical report of patient management and prescriptions behaviours for Schizophrenia, Bipolar disorders and Major depressive disorders.


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with one of the following conditions: Schizophrenia, Bipolar disorders and Major depressive disorders.

Exclusion Criteria:

* Patients who have not been diagnosed with the conditions as outlined in the Inclusion criteria.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06515496: A Clinical Trial to Examine the Efficacy of a Dietary Supplement to Improve the Health and Appearance of Hair.
Official title: A Clinical Trial to Examine the Efficacy of a Dietary Supplement to Improve the Health and Appearance of Hair.
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Hair Thinning
Hair Shedding
Keywords: Hair growth
Female pattern hair loss
Hair health
Lead sponsor: Scale Media Inc
Sponsor class: INDUSTRY
Collaborators: name: Citruslabs
First posted: 2024-07-23
Enrollment: 100
Sex: FEMALE
Minimum age (years): 35
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates the efficacy of Scale Media's HLV Clinical Formula Hair Vitamins on the health and appearance of hair, focusing on growth, volume, dullness, overall health, hair shedding, fullness, and strength. It is a randomized controlled trial with 50 female-at-birth participants experiencing self-perceived hair thinning.


Eligibility criteria: Inclusion Criteria:

* Female at birth, aged 35+.
* Self-perceived hair thinning and increased hair shedding for at least three months.
* Consistent hair care routine for at least one month prior.
* Willing to maintain hair care routine, diet, and refrain from new vitamins or supplements targeting hair growth during the study.
* Generally healthy without uncontrolled chronic diseases.

Exclusion Criteria:

* Hair loss conditions other than female pattern baldness.
* Pregnant, breastfeeding, or trying to conceive.
* Currently taking iron supplements or other hair growth treatments.
* Significant chronic conditions or planned medical procedures that interfere with protocol adherence.
* Recent chemical hair treatments or plans for such treatments during the study.
* Severe allergic reactions to the product's ingredients.
* Recent surgeries, major illnesses, or undergoing chemotherapy/radiotherapy.

Primary outcomes:
measure: Reduction in Hair Shedding
timeFrame: Baseline, Day 90, and Day 180
Secondary outcomes:
measure: Improvement in Hair Health Perception
timeFrame: Baseline, Day 30, Day 60, Day 90, Day 120, Day 150, and Day 180
Other outcomes:
Locations:
city: Santa Monica
country: United States
facility: Citruslabs
state: California
Study officials:
References:
Clinical trial NCT03027596: Remote Ischemic Conditioning to Reduce Burn Wound Progression
Official title: Remote Ischemic Conditioning to Reduce Burn Wound Progression
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Burns
Lead sponsor: BG Trauma Center Tuebingen
Sponsor class: OTHER
First posted: 2017-01-23
Enrollment: 140
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Burned skin areas, which were initially vital, can be irreversibly damaged by wound progression. The aim of the present study is to evaluate the feasibility of ischemic conditioning to reduce secondary wound progression.


Eligibility criteria: Inclusion Criteria:

* Ability to understand the study information and the consent to sign

  * Thermal injury (burn / scalding) with a clinical evaluated depth of at least 2a (superficial partial)
  * At least one of the following sites must not have skin lesions

    : Upper arm right and left
  * hospital admission within 6 hours after trauma has taken place

Exclusion Criteria:

* Participation in another experimental study

  * Pregnancy (women are subjected to a pregnancy test (urine)
  * Contraindication for the use of the tourniquet, for example Lymph drainage disorders after axillary lymphadenectomy or Irradiation of the axilla
  * Non-compliant patients who are, e.g. Intubated
  * Pure 3rd degree burns (full thickness) or charring
  * Thermal injuries older than 6 hours

Primary outcomes:
measure: Change of burn depth
timeFrame: day 0, 1, 2, 3, 4,5, 7, 11,18,21, 90,180
Secondary outcomes:
measure: Change in skin's relative amount of hemoglobin
timeFrame: day 0, 1, 2, 3, 4,5, 7, 11,18,21, 90,180
measure: Change in skin's blood flow
timeFrame: day 0, 1, 2, 3, 4,5, 7, 11,18,21, 90,180
measure: Change in skin's oxygen saturation
timeFrame: day 0, 1, 2, 3, 4,5, 7, 11,18,21, 90,180
measure: Change in skin elasticity
timeFrame: day 0, 1, 2, 3, 4,5, 7, 11,18,21, 90,180, 360
measure: Differences in scare development between the study groups
timeFrame: day 90, 180, 360
Other outcomes:
Locations:
city: Tuebingen
country: Germany
facility: BG Trauma Center, University Tübingen, Germany
Study officials:
affiliation: Hand and Plastic Surgery, BG Trauma Center Tübingen, Germany
name: Jens Rothenberger, M.D.
role: PRINCIPAL_INVESTIGATOR
References: